	manufacture moexipril tablet	17.883996438963642
¡°	stable moexipril magnesium tablet	14.995466295902004
	moexipril alkaline salt	14.682837926759026
	moexipril acid addition salt	13.394218085856993
	Univasc product	9.88877194464856
	sic moexipril hydrochloride formulation list	7.82987067933531
	Gu et al.1	3.946847237090305
	counsel	3.8137560675297943
	Uniretic	3.6517811614744695
	Gu article	3.639842152992855
	Gu teaching	3.6367179005303605
	magnesium oxide	3.4574783704192553
	magnesium hydroxide	3.2033084630036672
	alkaline stabilizer	2.970633892753852
¡°	alkaline magnesium compound	2.8536743567438667
	magnesium salt	2.1394861232080085
	alkaline saccharide stabilizer	1.9652650581564888
	ACE inhibitor magnesium carbonate	1.9105969982377768
	alkaline stabilize compound	1.4764468246142783
	alkaline stabilize agent	1.4727919587107297
	Moexipril Hydrochloride Tablets	1.4037428366559084
	Product Monograph	1.348564870658026
	ACE inhibitor drug	1.1875667382066506
	hypertension	1.1018819131051663
	wet granulation	1.0109326044234126
	dry granulation	0.9206896649323955
	UNVASC	0.9139301296335929
	chairman	0.5274637170719666
	lache	0.45751238164246916
	applicant herewith	0.45728884206643905
	neutralization	0.3674921156874893
	conversion	0.34753049883918335
	FDA Orange Book	0.3344357530696612
	Therapeutic Equivalence Evaluations	0.323536010506359
	Florida	0.3051727977078903
	solvent	0.29559432359302273
	stabilization result	0.2949566098707182
	Schwarz Pharma	0.2734066088831047
	degradation	0.2605713685160197
	process tablet	0.23128612868699924
	instability	0.22157215722355522
	cation salt	0.21939108420456285
	Counsel	0.18185901226795503
	dry powder mixing	0.16405865859578925
	founder	0.15266878893413524
	angiotensin convert enzyme	0.1442986593388405
	subsequent telephonic interview	0.14424499055558415
	Warner Lambert	0.12762374638537147
	granulated material	0.12258430004183567
	dry form	0.10584044403985188
	acid base reaction	0.09531219023399334
	skilled formulator	0.09302684733358169
	Examiner	0.09163218957448178
	drug formulation	0.08398641657091571
	Joint Appendix	0.08218411891479398
	J.A	0.07633439446706762
	dry material	0.07058049683628033
	uncertainty	0.05099380690032892
	canadian application	0.050892073206272204
	FDA Approved Drug Products	0.04801573555377008
	Harris	0.04643704001480071
	weak acid	0.044506078043207796
	Prosecution history	0.02308331501808861
	coverage	0.019511565621653463
	manufacturing process	0.018428906338256078
	full reconsideration	0.018143812773750295
	final formulation	0.01746347197363853
	first page	0.01398846447240693
	solid pharmaceutical composition	0.01378913803048091
	pharmaceutical industry	0.01263680542472126
	predetermine amount	0.012170111752060066
	inequitable conduct	0.010197546758819039
	approximately one hundred application	0.00964784055335825
	Prior Art	0.008841981200382695
	Southern District	0.008752328940423318
	Background section	0.008392969315158181
	outer surface	0.00756432167134416
	high blood pressure	0.007094400557914841
	priority	0.006132359155840585
	expert declaration	0.00540271782925236
	accordance	0.004772834560351645
	active ingredient	0.004718081762810486
	treatment	0.0045382235597557705
	preferred technique	0.004317138565618675
	PTO Board	0.003594451243819999
	April	0.0035627131299995956
	final composition	0.0028019505175390126
	preferred embodiment	0.002227649652505073
	hand	0.001681807642623981
	pre suit damage	0.0016577950945185819
	sole inventor	0.0013371802906283062
	July	0.0012491151590458957
	bench trial	0.0012452186331812995
	desire end result	0.0010354310866833492
	third final rejection	0.0007534233571526098
	a.	0.0006561604119830404
	discretion	0.0006239277339153986
	three obviousness rejection	0.0005939266265262724
	component	0.00048567730784817854
	control manner	0.00044671053913402926
	response	0.00034989948238574873
	final product	0.00033232057348296304
	sufficient amount	0.0002650068182901918
	obvious process	0.00015553865010074078
	several method	0.00014672479021874912
	competitor process	0.00013813750744108718
	portion	0.00013765319398427594
	additional example	0.0001318674519502983
	U.S. Patent Trademark Office	0.00011201177302856231
	prosecution	9.559138124868376e-05
	holding	9.013962396337808e-05
	background	8.77378875527711e-05
	two accuse product	8.366547884738925e-05
	independent	5.916253634941692e-05
	emphasis	4.522263716032062e-05
	obviousness ground	3.367369057074153e-05
	material fact	3.118436198002859e-05
	opinion	6.006862169967218e-06
	patentee	4.349945521724798e-06
	Idaho	3.4748467260060254e-06
	time	2.29609240345568e-06
	limitation	1.5915961783544607e-06
	cite reference	1.488659843451993e-06
	cite prior art	9.72373314756265e-07
	assert	7.653641344852267e-07
	conclusion	6.211540555528255e-07
	infringement action	1.7774581504924305e-07
	support	1.7190589198277964e-07
	district court judgment	4.928650333210989e-09
	Court	0.0
	Appeals	0.0
	Inc.	0.0
	United States	0.0
